Policy Forum
-Shahram Ahari
You are absolutely buying love.
-James Reidy [1] I n 2000, pharmaceutical companies spent more than 15.7 billion dollars on promoting prescription drugs in the United States [2] . More than 4.8 billion dollars was spent on detailing, the one-on-one promotion of drugs to doctors by pharmaceutical sales representatives, commonly called drug reps. The average sales force expenditure for pharmaceutical companies is $875 million annually [3] .
Unlike the door-to-door vendors of cosmetics and vacuum cleaners, drug reps do not sell their product directly to buyers. Consumers pay for prescription drugs, but physicians control access. Drug reps increase drug sales by infl uencing physicians, and they do so with fi nely titrated doses of friendship. This article, which grew out of conversations between a former drug rep (SA) and a physician who researches pharmaceutical marketing (AFB), reveals the strategies used by reps to manipulate physician prescribing.
Better Than You Know Yourself

During training, I was told, when you're out to dinner with a doctor, "The physician is eating with a friend. You are eating with a client." -Shahram Ahari
Reps may be genuinely friendly, but they are not genuine friends. Drug reps are selected for their presentability and outgoing natures, and are trained to be observant, personable, and helpful. They are also trained to assess physicians' personalities, practice styles, and preferences, and to relay this information back to the company. Personal information may be more important than prescribing preferences. Reps ask for and remember details about a physician's family life, professional interests, and recreational pursuits. A photo on a desk presents an opportunity to inquire about family members and memorize whatever tidbits are offered (including names, birthdays, and interests); these are usually typed into a database after the encounter. Reps scour a doctor's offi ce for objects-a tennis racquet, Russian novels, seventies rock music, fashion magazines, travel mementos, or cultural or religious symbols-that can be used to establish a personal connection with the doctor. Good details are dynamic; the best reps tailor their messages constantly according to their client's reaction. A friendly physician makes the rep's job easy, because the rep can use the "friendship" to request favors, in the form of prescriptions. Physicians who view the relationship as a straightforward goods-for-prescriptions exchange are dealt with in a businesslike manner. Skeptical doctors who favor evidence over charm are approached respectfully, supplied with reprints from the medical literature, and wooed as teachers. Physicians who refuse to see reps are detailed by proxy; their staff is dined and fl attered in hopes that they will act as emissaries for a rep's messages. (See Table 1 for specifi c tactics used to manipulate physicians.)
Gifts create both expectation and obligation. "The importance of developing loyalty through gifting cannot be overstated," writes Michael Oldani, an anthropologist and former drug rep [26] . Pharmaceutical gifting, however, involves carefully calibrated generosity. Many prescribers receive pens, notepads, and coffee mugs, all Drug reps usually feel more camaraderie with competing reps than they do with their clients. Thus, when a doctor fails to fulfi ll their end of the prescriptions-for-dinners bargain, news gets around and other reps are less likely to invest resources in them.
High-prescribers I rely on making a strong personal connection to those docs, something to make me stand out from the crowd.
Friendship sells. The highest prescribers (9's and 10's) are every reps sugar mommies and daddies. It's the equivalent of spitting in the ocean to try to buy these docs out because, chances are, every other rep is falling head over heels to do so.
The highest prescribers receive better presents. Some reps said their 10's might receive unrestricted "educational" grants so loosely restricted that they were the equivalent of a cash gift, although I did not personally provide any grants.
Prefers a competing drug
The fi rst thing I want to understand is why they're using another drug as opposed to mine. If it's a question of attention, then I commit myself to lavishing them with it until they're bought. If they are convinced that the competitor drug works better in some patient populations, I frame my drug to either capture another market niche or, if I feel my drug would fare well in a comparison, I hammer its superiority over the competing drug.
If, during the course of conversations, the doctors say something that may contradict their limited usage of our products, then the reps will badger them to justify that contradiction. This quickly transforms the rep from a welcomed reprieve to a nuisance, which can be useful in limited circumstances. We force the doctors to constantly explain their prescribing rationale, which is tiresome. Our intent is to engage in discourse but also to wear down the doc until he or she simply agrees to try the product for specifi c instances (we almost always argue for a specifi c patient profi le for our drugs).
For reps this is a core function of our job. We're trained to do this in as benign a way as possible. No doc likes to be told their judgment is wrong so the latter method typically requires some discretion.
Acquiescent docs
Most docs think that if they simply agree with what the rep says, they'll outsmart the rep by avoiding any confl ict or commitment, getting the samples and gifts they want, and fi nishing the encounter quickly. Nothing could be further from the truth. The old adage is true, especially in pharmaceutical sales: there is no such thing as a free lunch.
From the outset of my training, I've been taught to frame every conversation to ultimately derive commitments from my clients. With every acquiescent nod to statements of my drug's superiority I build the case for them to increase their usage of my product. They may offer me false promises but I'll know when they're lying: the prescribing data is suffi ciently detailed in my computer to confi rm their behavior. Doctors who fail to honor their commitments, no matter how casually made, convert the rep into a badgering nuisance. The docs are often corralled into a conversational corner where they have to justify their previous acquiescence.
Gifts are used to enhance guilt and social pressure. Reps know that gifts create a subconscious obligation to reciprocate. New reps who doubt this phenomenon need only see their doctors' prescribing data trending upwards to be convinced. Of course, most of these doctors think themselves immune to such infl uence. This is an illusion reps try to maintain.
items kept close at hand, ensuring that a targeted drug's name stays uppermost in a physician's subconscious mind. High prescribers receive higher-end presents, for example, silk ties or golf bags. As Oldani states, "The essence of pharmaceutical gifting…is 'bribes that aren't considered bribes'" [1] . Reps also recruit and audition "thought leaders" (physicians respected by their peers) to groom for the speaking circuit. Physicians invited and paid by a rep to speak to their peers may express their gratitude in increased prescriptions (see Table 1 ). Anything that improves the relationship between the rep and the client usually leads to improved market share. [5] . Pharmaceutical companies are the primary customers for prescribing data, which are used both to identify "highprescribers" and to track the effects of promotion. Physicians are ranked on a scale from one to ten based on how many prescriptions they write. Reps lavish high-prescribers with attention, gifts, and unrestricted "educational" grants (Table 1) . Cardiologists and other specialists write relatively few prescriptions, but are targeted because specialist prescriptions are perpetuated for years by primary care physicians, thus affecting market share.
Script Tracking
Reps use prescribing data to see how many of a physician's patients receive specifi c drugs, how many prescriptions the physician writes for targeted and competing drugs, and how a physician's prescribing habits change over time. One training guide states that an "individual market share report for each physician…pinpoints a prescriber's current habits" and is "used to identify which products are currently in favor with the physician Occasionally docs refuse to see reps. Some do it for ethical reasons, but most simply lack the time. Even when I don't manage to see the doctor, I can still make a successful call by detailing the staff. Although they're on the doc's side for the most part, it's amazing how much trouble one can rile up when the staff are lavished with food and gifts during a credible sounding presentation and then asked to discuss the usage of a drug on their patients.
It's a victory for me just to learn from the staff about which drugs are preferred, and why. That info provides powerful ammunition to debate the docs with on the rare occasions that I might see them. However, it's a greater success when the staff discusses my meds with the doc after I leave. Because while a message delivered by a rep gets discounted, a detail delivered by a co-worker slips undetected and unfi ltered under the guise of a conversation. And the response is usually better then what I might accomplish.
One's marketing success in a particular offi ce can be strongly correlated to one's success in providing good food for the staff. Goodwill from the staff provides me with critical information, access, and an advocate for me and my drug when I'm not there.
Thought leaders As a rep, I was always in pursuit of friendly "thought leaders" to groom for the speaking circuit. Once selected, a physician would give lectures around the district. I would carefully watch for tell-tale signs of their allegiance. This includes how they handled questions that criticized our product, how their prescribing habits fl uctuated, or simply how eager they were to give their next lecture.
The main target of these gatherings is the speaker, whose appreciation may be refl ected in increased prescribing of a company's products. Local speaking gigs are also auditions. Speakers with charisma, credentials, and an aura of integrity were elevated to the national circuit and, occasionally, given satellite telecast programs that offered CMEs.
Subtle and tactful spokespersons were the ideal candidates. I politely dismissed doctors who would play cheerleader for any drug…at the right price, of course. in order to develop a strategy to change those prescriptions into Merck prescriptions" [6] . A Pharmaceutical Executive article states, "A physician's prescribing value is a function of the opportunity to prescribe, plus his or her attitude toward prescribing, along with outside infl uences. By building these multiple dimensions into physicians' profi les, it is possible to understand the 'why' behind the 'what' and 'how' of their behavior." [7] To this end, some companies combine data sources. For example, Medical Marketing Service "enhances the AMA Masterfi le with non-AMA data from a variety of sources to not only include demographic selections, but also behavioral and psychographic selections that help you to better target your perfect prospects" [8] .
The goal of this demographic slicing and dicing is to identify physicians who are most susceptible to marketing efforts. One industry article suggests categorizing physicians as "hidden gems": "Initially considered 'low value' because they are low prescribers, these physicians can change their prescribing habits after targeted, effective marketing." "Growers" are "Physicians who are early adopters of a brand. Pharmaceutical companies employ retention strategies to continue to reinforce their growth behavior." Physicians are considered "low value" "due to low category share and prescribing level" [9] .
In an interview with Pharmaceutical Representative, Fred Marshall, president of Quantum Learning, explained, "… One type might be called 'the spreader' who uses a little bit of everybody's product. The second type might be a 'loyalist', who's very loyal to one particular product and uses it for most patient types. Another physician might be a 'niche' physician, who reserves our product only for a very narrowly defi ned patient type. And the idea in physician segmentation would be to have a different messaging strategy for each of those physician segments " [10] .
In Pharmaceutical Executive, Ron Brand of IMS Consulting writes "…integrated segmentation analyzes individual prescribing behaviors, demographics, and psychographics (attitudes, beliefs, and values) to fi netune sales targets. For a particular product, for example, one segment might consist of price-sensitive physicians, another might include doctors loyal to a given manufacturers brand, and a third may include those unfriendly towards reps" [11] .
In recent years, physicians have become aware of-and dismayed by-script tracking. In July 2006, the AMA launched the Prescribing Data Restriction Program (see http:⁄⁄www.ama-assn.org/ama/pub/ category/12054.html), which allows physicians the opportunity to withhold most prescribing information from reps and their supervisors (anyone above that level, however, has full access to all data). According to an article in Pharmaceutical Executive, "Reps and direct managers can view the physician's prescribing volume quantiled at the therapeutic class level" and can still view aggregated or segmented data including "categories into which the prescriber falls, such as an early-adopter of drugs, for example…." [12] . The pharmaceutical industry supports the Prescribing Data Restriction Program, which is seen as a less onerous alternative to, for example, state legislation passed in New Hampshire forbidding the sale of prescription data to commercial entities [13] .
The Value of Samples
The purpose of supplying drug samples is to gain entry into doctors' offi ces, and to habituate physicians to prescribing targeted drugs. Physicians appreciate samples, which can be used to start therapy immediately, test tolerance to a new drug, or reduce the total cost of a prescription. Even physicians who refuse to see drug reps usually want samples (these docs are denigrated as "samplegrabbers"). Patients like samples too; it's nice to get a little present from the doctor. Samples also double as unacknowledged gifts to physicians and their staff. The convenience of an in-house pharmacy increases loyalty to both the reps and the drugs they represent.
Some physicians use samples to provide drugs to indigent patients [14, 15] . Using samples for an entire course of treatment is anathema to pharmaceutical companies because this "cannibalizes" sales. Among the aims of one industry sample-tracking program are to "reallocate samples to highopportunity prescribers most receptive to sampling as a promotional vehicle" and "identify prescribers who were oversampled and take corrective action immediately" [16] .
Studies consistently show that samples infl uence prescribing choices [14, 15, 17] . Reps provide samples only of the most promoted, usually most expensive, drugs, and patients given a sample for part of a course of treatment almost always receive a prescription for the same drug. Physicians view drug information provided by reps as a convenient, if not entirely reliable, educational service. An industry survey found that more than half of "high-prescribing" doctors cited drug reps as their main source of information about new drugs [22] . In another study, three quarters of 2,608 practicing physicians found information provided by reps "very useful" (15%) or "somewhat useful" (59%) [23] . However, only 9% agreed that the information was "very accurate"; 72% thought the information was "somewhat accurate"; and 14% said that it was "not very" or "not at all" accurate.
Funding Friendship
Whether or not physicians believe in the accuracy of information provided, detailing is extremely effective at changing prescribing behavior, which is why it is worth its substantial expense. The average annual income for a drug rep is $81,700, which includes $62,400 in base salary plus $19,300 in bonuses. The average cost of recruiting, hiring, and training a new rep is estimated to be $89,000 [24] . When expenses are added to income and training, pharmaceutical companies spend $150,000 annually per primary care sales representative and $330,000 per specialty sales representative [25] . An industry article states, "The pharmaceutical industry averages $31.9 million in annual sales spending per primary-care drug…Sales spending for specialty drugs that treat a narrowed population segment average $25.3 million per product across the industry." [25] 
Conclusion
As one of us (SA) explained in testimony in the litigation over New Hampshire's new ban on the commercial sale of prescription data, the concept that reps provide necessary services to physicians and patients is a fi ction. Pharmaceutical companies spend billions of dollars annually to ensure that physicians most susceptible to marketing prescribe the most expensive, most promoted drugs to the most people possible. The foundation of this infl uence is a sales force of 100,000 drug reps that provides rationed doses of samples, gifts, services, and fl attery to a subset of physicians. If detailing were an educational service, it would be provided to all physicians, not just those who affect market share.
Physicians are susceptible to corporate infl uence because they are overworked, overwhelmed with information and paperwork, and feel underappreciated. Cheerful and charming, bearing food and gifts, drug reps provide respite and sympathy; they appreciate how hard doctor's lives are, and seem only to want to ease their burdens. But, as SA's New Hampshire testimony refl ects, every word, every courtesy, every gift, and every piece of information provided is carefully crafted, not to assist doctors or patients, but to increase market share for targeted drugs (see Table 1 ). In the interests of patients, physicians must reject the false friendship provided by reps. Physicians must rely on information on drugs from unconfl icted sources, and seek friends among those who are not paid to be friends.
